Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort - Wikidata - awgldk - TriplyDB

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

http://www.wikidata.org/entity/Q36316145

about

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Splanchnic vein thrombosis in myeloproliferative neoplasms.Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Cerebral thrombosis and myeloproliferative neoplasms.How we diagnose and treat essential thrombocythaemia.Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count.Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes.Pregnancy and myeloproliferative neoplasms : A retrospective monocentric cohort.Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.SOHO State-of-the-Art Update and Next Questions: MPN.Ruxolitinib for essential thrombocythemia?Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.

P2860

Q28074777-8826BE99-C7E5-4D1D-AD1D-93CC4D930A46 Q30276550-7B6265B8-AE62-4F0F-BDF9-4F94F766F8A0 Q34370771-1F0B19D1-A6BA-4890-9B80-9E24813714C9 Q36654317-A4589EF3-1015-430B-AA43-019ADA58E744 Q36666769-D0B770CD-5FE0-4DE7-B0E1-F21EB1FBE67B Q37328478-21A9822D-13C9-455C-9AFA-3B655D4F936C Q37679175-0A43DC32-EE53-42FA-98C8-AC67BEB2E106 Q38087202-58982E61-D313-43BA-9C5F-DFD8FCF8590D Q38100371-2CAA28D0-C361-41CB-AB48-C288A903E6C4 Q38121635-60CB36FC-61D6-46FB-9FB0-157EE0E5451E Q38187674-B5EC43A8-D875-4908-A223-AAC60221AF69 Q38210664-6AD2A016-891A-4F16-BEAB-C2CC78AF8B53 Q38248785-EFB37D74-7B8C-48C2-A350-E32B770506F6 Q38606595-7886F8E6-85C3-4887-8232-48EBF7B98734 Q38742500-FC899D18-95FD-4474-8747-498698050D3D Q39041471-C3376071-A90F-46C7-B615-9D47B516514E Q39059693-A012955D-7D5F-45C1-9A51-EFF69C1D57AF Q39309957-77E5E800-36C3-4056-9684-2ADCD6ADD65D Q39321106-FD7DF900-5D16-4349-9409-CC0CA86DD6AF Q39869975-A92CCA7F-B2D0-4E79-B950-7BE407228892 Q40125614-D66A955B-417C-4B5A-B777-02940A0816C6 Q41257287-1BBFE0AF-8A23-4E1E-A3D4-479E06845047 Q42609605-E573A384-57EC-408A-8B0D-43C7A3DB905D Q47294481-5E49404B-39EF-48C8-88BD-B055FA2E4E0A Q47296896-C330016C-2AC8-4631-99B1-200D4B097243 Q47334212-C1BF6B99-E78C-4A27-8E11-C17471D3C26E Q47699454-67C20C59-3F19-4624-98E0-716A2F1A9C14 Q47929354-84BA9DAB-B426-480B-975C-6A17B12040A3 Q49580473-07A245BC-6A4C-4DDB-BD83-075FC8912ABC Q49727337-A691DB62-D59C-4EE5-A86A-F078A796CF1E Q52859278-85069104-8CAC-4996-BBB0-1CAD8B0ECEB1 Q52951456-C14A9B20-0A87-4A33-A03A-13D4CD64C84C Q53096238-5848B754-3A22-40EB-AB01-2C2F33AA7863

P2860

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

http://www.wikidata.org/entity/Q36316145

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Correlation of blood counts wi ...... of the prospective PT1 cohort

@ast

Correlation of blood counts wi ...... of the prospective PT1 cohort

@en

type

label

Correlation of blood counts wi ...... of the prospective PT1 cohort

@ast

Correlation of blood counts wi ...... of the prospective PT1 cohort

@en

prefLabel

Correlation of blood counts wi ...... of the prospective PT1 cohort

@ast

Correlation of blood counts wi ...... of the prospective PT1 cohort

@en

P1433

Q36316145-3E8330D0-A01D-4BCF-8EE0-F81AD53C7B76

P1476

Q36316145-91DB21FD-93E2-4222-9DE1-036A87665E6A

P2093

Q36316145-342BC8CA-06E9-46D7-94D4-360F638B27A2

Q36316145-363D270A-D395-4ABE-8FD2-C508BF1FBF0D

Q36316145-6A46D81A-BFE1-4590-8E5C-6A0211BAF604

Q36316145-85BE1840-ADEC-4042-A335-2B59BB09DE9E

Q36316145-9225031F-8367-4C51-A1B1-C756785F654A

Q36316145-A3A905A4-5BA0-42CE-9C71-216AD4D665C7

Q36316145-A5C7023B-7E9D-4D45-B987-AE44095A07D0

Q36316145-CA7C7FDC-3057-43A5-9352-666B89EC8B24

Q36316145-DD288206-128A-40C8-A9C1-697D481B6AD8

P2860

Q36316145-0BB4EBD8-D5A4-4EFF-88AE-0534AEB3EEDD

Q36316145-0E57F139-1AAB-4C37-B3EF-CFAE990BDA03

Q36316145-212355B9-FFEC-4EFB-A299-4492E96279AD

Q36316145-31B41453-7024-4691-A9EF-BF031378CB83

Q36316145-36B1FBFE-9A92-41CC-AF8E-3D4BE44CC6E7

Q36316145-37EDAC9D-FF43-42C5-AF65-75B5A8CEE1FF

Q36316145-6FBDD737-5E1F-4995-A0A2-A172BE78C34B

Q36316145-84D0166C-34F7-41E6-A97C-D0143D092D15

Q36316145-8D7AA4FF-FDBC-48BB-9D5A-C25058A59197

Q36316145-946FAA16-A2CD-4EE9-AD94-3EFEB267720E

P304

Q36316145-B7F5C7C9-4496-41A3-AB3D-C1B2B095D9AA

P31

Q36316145-8A6C7214-5DF3-402E-8BC2-F57796AC5A9D

P356

Q36316145-476A499D-C153-440F-9237-DCB2AE7CE7C9

P407

Q36316145-666CCBCD-6240-49D5-83F4-4C20517264F0

P433

Q36316145-45720662-9137-411D-8216-682F65A143AE

P478

Q36316145-24B08A37-4000-47AD-A1EA-10DD8F10C37E

P577

Q36316145-0535F8C9-86EC-4A9C-BA35-7C0B14399597

P5875

Q36316145-712AF1B6-53F7-4125-9B86-33BDC1E95A4F

P698

Q36316145-3EF6F1C3-4181-4E33-BE3C-F55BA8F679BB

P932

Q36316145-3EA296F9-6920-4F26-A001-B8E57D07B847

P356

BLOOD-2012-04-424911

P1433

P1476

Correlation of blood counts wi ...... of the prospective PT1 cohort

@en

P2093

Anthony R Green

http://www.w3.org/2001/XMLSchema#string

Cathy MacLean

http://www.w3.org/2001/XMLSchema#string

Cecily Forsyth

http://www.w3.org/2001/XMLSchema#string

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

Georgina Buck

http://www.w3.org/2001/XMLSchema#string

Jean-Jacques Kiladjian

http://www.w3.org/2001/XMLSchema#string

Keith Wheatley

http://www.w3.org/2001/XMLSchema#string

Peter J Campbell

http://www.w3.org/2001/XMLSchema#string

Philip A Beer

http://www.w3.org/2001/XMLSchema#string

P2860

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

Guideline for investigation and management of adults and children presenting with a thrombocytosis

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

P304

1409-1411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-04-424911

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227341415

http://www.w3.org/2001/XMLSchema#string

P698

22709688

http://www.w3.org/2001/XMLSchema#string

P932

3470936

http://www.w3.org/2001/XMLSchema#string